Key facts
- EpiBiologics’s last known valuation is $210.0M (Oct 2025).
- It has raised $180.0M across 1 recorded rounds; the latest was Later Stage VC ($73.0M) in Mar 2022.
- Notable investors include GV, Johnson & Johnson JJDC, Polaris Partners, Digitalis Ventures, Samsara BioCapital — 13 tracked in total.
- EpiBiologics has filed 2 Form Ds with the SEC since 2023, most recently Apr 2024 ($73.0M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for EpiBiologics
Funding rounds
1 roundsAbout EpiBiologics
Developer of protein degradation therapeutics designed to address disease-causing proteins through targeted degradation. The company specializes in antibody-based targeted therapies against the membrane and extracellular proteins, leveraging a modular system of bifunctional binding agents with a diverse atlas of tissue-selective surface receptors, enabling researchers to manipulate cellular proteostasis for the treatment of the disease.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2022
- Employees
- 43
- Website
- epibiologics.com/
- Ownership
- Privately Held (backing)
EpiBiologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EpiBiologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EpiBiologics in its N-PORT filings yet. We sweep new filings monthly.